首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   911513篇
  免费   74663篇
  国内免费   1872篇
耳鼻咽喉   13541篇
儿科学   26228篇
妇产科学   26327篇
基础医学   131761篇
口腔科学   27440篇
临床医学   80054篇
内科学   173322篇
皮肤病学   18289篇
神经病学   75606篇
特种医学   37567篇
外国民族医学   171篇
外科学   143113篇
综合类   24772篇
现状与发展   2篇
一般理论   292篇
预防医学   70211篇
眼科学   21562篇
药学   68228篇
中国医学   1669篇
肿瘤学   47893篇
  2018年   8511篇
  2016年   7854篇
  2015年   8751篇
  2014年   12295篇
  2013年   19021篇
  2012年   25535篇
  2011年   27091篇
  2010年   15527篇
  2009年   14121篇
  2008年   25784篇
  2007年   27964篇
  2006年   27669篇
  2005年   27213篇
  2004年   26660篇
  2003年   25820篇
  2002年   24795篇
  2001年   37924篇
  2000年   39190篇
  1999年   32354篇
  1998年   9672篇
  1997年   8934篇
  1996年   8780篇
  1995年   8261篇
  1994年   7984篇
  1992年   26885篇
  1991年   26289篇
  1990年   25805篇
  1989年   24902篇
  1988年   23389篇
  1987年   23073篇
  1986年   21929篇
  1985年   21334篇
  1984年   16669篇
  1983年   14223篇
  1982年   9022篇
  1981年   8332篇
  1980年   7787篇
  1979年   16887篇
  1978年   12214篇
  1977年   10294篇
  1976年   9441篇
  1975年   10247篇
  1974年   12713篇
  1973年   12255篇
  1972年   11598篇
  1971年   10731篇
  1970年   10264篇
  1969年   9964篇
  1968年   8985篇
  1967年   8273篇
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
21.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
22.
23.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
24.
25.
26.
27.
28.
29.
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号